Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7522855 | 1.00 | CETP (0.43) | CETPPKMALDH1A1LMNAHTT | |
| SCHEMBL7532833 | 1.00 | CETP (0.43) | CETPPKMALDH1A1LMNAHTT | |
| SCHEMBL6230212 | 0.85 | CETP (0.56) | CETPPKMLMNAHTTKMT2A | |
| SCHEMBL7531864 | 0.84 | LMNA (0.42) | CETPPKMLMNAKMT2A | |
| SCHEMBL7527645 | 0.84 | LMNA (0.42) | CETPPKMLMNAKMT2A | |
| SCHEMBL7527642 | 0.84 | LMNA (0.42) | CETPPKMLMNAKMT2A | |
| SCHEMBL7531868 | 0.84 | LMNA (0.42) | CETPPKMLMNAKMT2A | |
| SCHEMBL18471527 | 0.81 | TSHR (0.32) | CETPALDH1A1 | |
| SCHEMBL1492602 | 0.74 | CETP (0.46) | CETPPKMALDH1A1LMNAHTT | |
| SCHEMBL4547683 | 0.74 | TSHR (0.48) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10195004-A | — | — | None | — | — | JP | disclosed |
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-12-05 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-10-19 | — | — | US | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200246474-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2020-08-06 | — | — | US | disclosed |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-0937765-B1 | Ferrielectric liquid crystal compound | MITSUBISHI GAS CHEMICAL CO (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-0842915-B1 | Optically active alcohol and process for the production thereof | MITSUBISHI GAS CHEMICAL CO (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-0853076-B1 | Liquid crystal compound | MITSUBISHI GAS CHEMICAL CO (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6128065-A | 2 OR 3-FLUORO SUBSTITUTED OR UNSUBSTITUTED 4-(1-TRIFLUOROMETHYL-4-METHYL-PENTYL OR HEXYLOXYCARBONYL)PHENYL-4'-N-ALKYLBIPHENYL-4-CARBOXYLATE CONTAINING ASYMMETRIC CARBON ATOM | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6002042-A | Liquid crystal compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0937765-A1 | Ferrielectric liquid crystal compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1999-08-25 | — | — | EP | disclosed |
| JP-H10195004-A | OPTICALLY ACTIVE ALCOHOL AND ITS PRODUCTION | MITSUBISHI GAS CHEM CO INC | 1998-07-28 | — | — | JP | disclosed |
| EP-0853076-A1 | Liquid crystal compound | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-07-15 | — | — | EP | disclosed |
| EP-0842915-A2 | Optically active alcohol and process for the production thereof | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833210-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | CETP 2252/4885PKM 3230/4885ALDH1A1 802/4885 |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | CETP 2393/4885PKM 3634/4885ALDH1A1 1880/4885 |
| US-10632209-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | CETP 2252/4885PKM 3230/4885ALDH1A1 802/4885 |
| US-20150158879-A1 | Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection | ADORA3, ADORA1, BRS3 | CETP 3724/4885PKM 3581/4885ALDH1A1 943/4885 |
| US-20200246474-A1 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH | ASH1L, DOT1L, ASH2L | CETP 2252/4885PKM 3230/4885ALDH1A1 802/4885 |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | CETP 4316/4885PKM 926/4885ALDH1A1 600/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | CETP 2393/4885PKM 3634/4885ALDH1A1 1880/4885 |
| US-11147885-B2 | ASH1L inhibitors and methods of treatment therewith | ASH1L, DOT1L, ASH2L | CETP 2252/4885PKM 3230/4885ALDH1A1 802/4885 |
| US-11633490-B2 | — | ASH1L, ASH2L, STUB1 | CETP 2533/4885PKM 3682/4885ALDH1A1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.